Literature DB >> 15070496

Assessing instruments in a Cuban American population with type 2 diabetes mellitus.

Barbara S Morgan1, Charles P Buscemi, Vivian P Fajardo.   

Abstract

The purposes of this pilot study were to identify and adapt instruments for future use in assessing diabetes self-management in a sample of Cuban Americans with Type 2 diabetes. Eight instruments were selected from the literature, translated into Spanish, and administered to a sample of 20 Cuban Americans with Type 2 diabetes. Psychometric properties were examined along with clarity of wording, cultural appropriateness, and ease of use. Reliability data were compared, when possible, with original scores generated with non-Cuban populations. Results indicated that reliability scores among populations were similar. Support for using these instruments in clinical practice to assess initial knowledge and beliefs about aspects of diabetes management and to monitor changes is provided.

Entities:  

Mesh:

Year:  2004        PMID: 15070496     DOI: 10.1177/1043659603262487

Source DB:  PubMed          Journal:  J Transcult Nurs        ISSN: 1043-6596            Impact factor:   1.959


  3 in total

Review 1.  Cuban Americans (CAs) and Type 2 Diabetes: An Integrative Review of the Literature.

Authors:  Heather E Cuevas; Sharon A Brown
Journal:  J Immigr Minor Health       Date:  2017-10

2.  Measurement Properties of Patient-Reported Outcome Measures for Diabetes: Systematic Review.

Authors:  Priscilla Jia Ling Wee; Yu Heng Kwan; Dionne Hui Fang Loh; Jie Kie Phang; Troy H Puar; Truls Østbye; Julian Thumboo; Sungwon Yoon; Lian Leng Low
Journal:  J Med Internet Res       Date:  2021-08-13       Impact factor: 5.428

Review 3.  Patient-reported outcome measures for assessing health-related quality of life in people with type 2 diabetes: A systematic review.

Authors:  Marlous Langendoen-Gort; Lenka Groeneveld; Cecilia A C Prinsen; Joline W Beulens; Petra J M Elders; Ilana Halperin; Geetha Mukerji; Caroline B Terwee; Femke Rutters
Journal:  Rev Endocr Metab Disord       Date:  2022-07-02       Impact factor: 9.306

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.